Alpha-Synuclein Neurobiology in Parkinson’s Disease: A Comprehensive Review of Its Role, Mechanisms, and Therapeutic Perspectives
Jamir Pitton Rissardo(Cooper University Hospital), George T. Kannarkat(Philadelphia VA Medical Center), Andrew McGarry(Cooper Medical School of Rowan University), Ana Letícia Fornari Caprara(Cooper University Hospital), Yiwen Shi(Cooper University Hospital)
Cited by 8
Related Papers
A randomized, double-blind, placebo-controlled trial of coenzyme Q10 in Huntington disease
|Neurology|2016|137
Safety, tolerability, and efficacy of NLY01 in early untreated Parkinson's disease: a randomised, double-blind, placebo-controlled trial
|The Lancet Neurology|2023|128
Safety and efficacy of pridopidine in patients with Huntington's disease (PRIDE-HD): a phase 2, randomised, placebo-controlled, multicentre, dose-ranging study
|The Lancet Neurology|2018|108
Pharmacologic approaches to the treatment of Huntington's disease
|Movement Disorders|2011|84